Inhibikase adds cardiologist Scott Wasserman to its board

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced the appointment of Scott M. Wasserman, MD, to its board of directors, effective October 19, 2026, concurrent with the resignation of Dennis Berman from the board.

Dr. Wasserman currently serves as Chief Medical Officer of Kailera Therapeutics. He previously held the role of Vice President, Global Development and Therapeutic Area Head for Bone, Cardiovascular, Metabolic and Neuroscience at Amgen Inc., where he led the global development and approval of Repatha (evolocumab), and was involved in the approvals of Evenity (romosozumab) and Aimovig (erenumab).

Prior to Kailera, Dr. Wasserman served as Venture Partner at Frazier Life Sciences and was CEO and co-founder of Latigo Biotherapeutics. He received his MD, Magna Cum Laude, from Harvard Medical School and completed postgraduate training at Stanford University.

"Scott has taken multiple programs from early development through global approval, and he has built clinical organizations at both large and emerging companies," said Amit Munshi, Chair of the Inhibikase board.

Inhibikase is currently conducting a Phase 3 clinical study, IMPROVE-PAH, evaluating IKT-001, a prodrug of imatinib, as a treatment for Pulmonary Arterial Hypertension across approximately 180 sites globally.

You May Also Be Interested In

• Compass Therapeutics publishes Phase 2/3 biliary cancer trial results
• Tango reports 82% response rate in pancreatic cancer drug study
• Actinium to present ATNM-400 prostate cancer trial data at ESMO 2026